litlas
Log inCreate account

Simon L. Croft

Active 1984–2021

Also published as
Simon L Croft
98
Papers
19,046
Citations
77
h-index
98
i10-index

Citations

Citations per year for Simon L. Croft1980: 1 citations1986: 1 citations1987: 2 citations1992: 4 citations1993: 5 citations1994: 4 citations1995: 6 citations1996: 7 citations1997: 12 citations1998: 15 citations1999: 18 citations2000: 24 citations2001: 40 citations2002: 49 citations2003: 125 citations2004: 114 citations2005: 152 citations2006: 198 citations2007: 167 citations2008: 164 citations2009: 212 citations2010: 167 citations2011: 209 citations2012: 155 citations2013: 111 citations2014: 134 citations2015: 92 citations2016: 85 citations2017: 84 citations2018: 80 citations2019: 438 citations2020: 484 citations2021: 430 citations2022: 281 citations2023: 146 citations2024: 308 citations2025: 80 citations2026: 1 citations1981–1985: no citations, so these years are not shown1988–1991: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 662 citing papers, 12.5% of this breakdownUnited Kingdom: 523 citing papers, 9.9% of this breakdownBrazil: 494 citing papers, 9.3% of this breakdownIndia: 463 citing papers, 8.7% of this breakdownSpain: 244 citing papers, 4.6% of this breakdownSwitzerland: 214 citing papers, 4% of this breakdownGermany: 206 citing papers, 3.9% of this breakdownFrance: 187 citing papers, 3.5% of this breakdownBelgium: 140 citing papers, 2.7% of this breakdownChina: 129 citing papers, 2.4% of this breakdownIran: 115 citing papers, 2.2% of this breakdownItaly: 115 citing papers, 2.2% of this breakdown
0%12.5%Other 34.1%

Institutions

Fields

  • Medicine71.9%
  • Biochemistry, Genetics and Molecular Biology10.1%
  • Chemistry4.6%
  • Pharmacology, Toxicology and Pharmaceutics3.5%
  • Immunology and Microbiology3.4%
  • Computer Science2.2%
  • Other4.3%

Topics

  • Research on Leishmaniasis Studies20.5%
  • Trypanosoma species research and implications13.1%
  • Malaria Research and Control5%
  • Parasites and Host Interactions4.2%
  • Computational Drug Discovery Methods3.4%
  • Synthesis and Biological Evaluation3.4%
  • Other50.4%

Coauthors

All papers

Open in search
  1. Leishmaniasis

    Authors: Sakib Burza, Simon L. Croft, Marleen Boelaert - The Lancet 2018 cited by 1,908

  2. Drug Resistance in Leishmaniasis

    Authors: Simon L. Croft, Shyam Sundar, Alan H. Fairlamb - Clinical Microbiology Reviews 2006 cited by 1,664

  3. A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission

    Authors: David A. Baker, Lindsay B. Stewart, Jonathan M. Large, Paul W. Bowyer, Keith H. Ansell, Marı́a Belén Jiménez-Dı́az, M. El Bakkouri, Kristian Birchall, Koen J. Dechering, Nathalie Bouloc, P.J. Coombs, David Whalley, Denise J. Harding, Ela Smiljanic-Hurley, Mary C. Wheldon, Eloise M. Walker, Johannes T. Dessens, María José Lafuente, Laura M. Sanz, Francisco‐Javier Gamo, Santiago Ferrer, Raymond Hui, Teun Bousema, Íñigo Angulo‐Barturen, Andy Merritt, Simon L. Croft, Winston E. Gutteridge, Catherine Kettleborough, Simon A. Osborne - Nature Communications 2017 cited by 185

  4. Leishmaniasis– current chemotherapy and recent advances in the search for novel drugs

    Authors: Simon L. Croft, Graham H. Coombs - Trends in Parasitology 2003 cited by 885

  5. Kinetoplastids: related protozoan pathogens, different diseases

    Authors: Ken Stuart, Reto Brun, Simon L. Croft, Alan H. Fairlamb, Ricardo E. Gürtler, Jim McKerrow, Steve Reed, Rick L. Tarleton - Journal of Clinical Investigation 2008 cited by 619

  6. 2- and 3-Substituted 1,4-Naphthoquinone Derivatives as Subversive Substrates of Trypanothione Reductase and Lipoamide Dehydrogenase from Trypanosoma cruzi: Synthesis and Correlation between Redox Cycling Activities and in Vitro Cytotoxicity

    Authors: Laurence Salmon-Chemin, Eric Buisine, Vanessa Yardley, Sven Köhler, Marie-Ange Debreu, Valérie Landry, Christian Sergheraert, Simon L. Croft, R. Luise Krauth‐Siegel, Elisabeth Davioud–Charvet - Journal of Medicinal Chemistry 2001 cited by 257

  7. Review of pyronaridine anti-malarial properties and product characteristics

    Authors: Simon L. Croft, Stephan Duparc, Sarah Arbe‐Barnes, J. Carl Craft, Changsik Shin, Lawrence Fleckenstein, Isabelle Borghini-Fuhrer, Han-Jong Rim - Malaria Journal 2012 cited by 158

  8. Antimalarial drug discovery: efficacy models for compound screening

    Authors: David A. Fidock, Philip J. Rosenthal, Simon L. Croft, Reto Brun, Solomon Nwaka - Nature Reviews Drug Discovery 2004 cited by 864

  9. Natural products as antiparasitic drugs

    Authors: Oliver Kayser, Albrecht F. Kiderlen, Simon L. Croft - Parasitology Research 2003 cited by 370

  10. Case study for a vaccine against leishmaniasis

    Authors: Jorge Alvar, Simon L. Croft, Paul M. Kaye, Ali Khamesipour, Shyam Sundar, Steven G. Reed - Vaccine 2013 cited by 121

  11. Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis

    Authors: Alaa Riezk, Katrien Van Bocxlaer, Vanessa Yardley, Sudaxshina Murdan, Simon L. Croft - Molecules 2020 cited by 79

  12. Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis

    Authors: Katrien Van Bocxlaer, Diana Caridha, Chad Black, Brian A. Vesely, Susan E. Leed, Richard J. Sciotti, Gert-Jan Wijnant, Vanessa Yardley, Stéphanie Braillard, Charles E. Mowbray, Jean‐Robert Ioset, Simon L. Croft - International Journal for Parasitology Drugs and Drug Resistance 2019 cited by 67

  13. Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis

    Authors: Gert-Jan Wijnant, Simon L. Croft, Raúl de la Flor, Mohammad S. Alavijeh, Vanessa Yardley, Stéphanie Braillard, Charles E. Mowbray, Katrien Van Bocxlaer - Antimicrobial Agents and Chemotherapy 2019 cited by 41

  14. Leishmaniasis – Authors' reply

    Authors: Sakib Burza, Simon L. Croft, Marleen Boelaert - The Lancet 2019 cited by 35

  15. Leishmaniasis chemotherapy—challenges and opportunities

    Authors: Simon L. Croft, Piero Olliaro - Clinical Microbiology and Infection 2011 cited by 427

  16. Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use

    Authors: F. Javier Pérez‐Victoria, María P. Sánchez‐Cañete, Karin Seifert, Simon L. Croft, Shyam Sundar, Santiago Castanys, Francisco Gamarro - Drug Resistance Updates 2006 cited by 211

  17. In Vitro and In Vivo Interactions between Miltefosine and Other Antileishmanial Drugs

    Authors: Karin Seifert, Simon L. Croft - Antimicrobial Agents and Chemotherapy 2005 cited by 205

  18. Synthesis and Evaluation of Cryptolepine Analogues for Their Potential as New Antimalarial Agents

    Authors: Colin W. Wright, Jonathan Addae-Kyereme, Anthony G. Breen, John E. Brown, Marlene F. Cox, Simon L. Croft, Yaman Gökçek, Howard Kendrick, Roger M. Phillips, Paméla Pollet - Journal of Medicinal Chemistry 2001 cited by 190

  19. Miltefosine – discovery of the antileishmanial activity of phospholipid derivatives

    Authors: Simon L. Croft, Juergen Engel - Transactions of the Royal Society of Tropical Medicine and Hygiene 2006 cited by 180

  20. Marine alkaloids as bioactive agents against protozoal neglected tropical diseases and malaria

    Authors: André G. Tempone, Pauline Pieper, Samanta Etel Treiger Borborema, Fernanda Thevenard, João Henrique G. Lago, Simon L. Croft, Edward A. Anderson - Natural Product Reports 2021 cited by 54

  21. Activity of Chitosan and Its Derivatives against Leishmania major and Leishmania mexicana In Vitro

    Authors: Alaa Riezk, John G. Raynes, Vanessa Yardley, Sudaxshina Murdan, Simon L. Croft - Antimicrobial Agents and Chemotherapy 2019 cited by 35

  22. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda

    Authors: Philippe J. Guérin, Piero Olliaro, Shyam Sundar, Marleen Boelaert, Simon L. Croft, P. Desjeux, Monique Wasunna, A.D.M. Bryceson - The Lancet Infectious Diseases 2002 cited by 766

  23. Current scenario of drug development for leishmaniasis.

    Authors: Simon L. Croft, Karin Seifert, Vanessa Yardley - 2006 cited by 392

  24. Chemotherapy of Leishmaniasis

    Authors: Simon L. Croft, Vanessa Yardley - Current Pharmaceutical Design 2002 cited by 377